CNS Pharmaceuticals, Inc.
CNSPDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Berubicin | Phase 2 | Glioblastoma Multiforme, Adult | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in CNS Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in CNS Pharmaceuticals, Inc.'s (CNSP) pipeline across Phase 2. Its lead program is Berubicin (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is CNS Pharmaceuticals, Inc.'s next FDA catalyst?→
CNS Pharmaceuticals, Inc.'s (CNSP) next tracked catalyst is a Earnings expected November 13, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CNSP biotech catalysts?→
Add CNSP to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow CNS Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.